title: Clinical course of four patients receiving the experimental antiviral agent fialuridine for the treatment of chronic hepatitis B infection.
authors.affiliation: Department of Surgery, University of Virginia Health Science Center, Charlottesville 22908.
authors.forename: W
authors.initials: W
authors.lastname: Stevenson
authors.forename: M
authors.initials: M
authors.lastname: Gaffey
authors.forename: M
authors.initials: M
authors.lastname: Ishitani
authors.forename: C
authors.initials: C
authors.lastname: McCullough
authors.forename: R
authors.initials: R
authors.lastname: Dickson
authors.forename: S
authors.initials: S
authors.lastname: Caldwell
authors.forename: P
authors.initials: P
authors.lastname: Lobo
authors.forename: T
authors.initials: T
authors.lastname: Pruett
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use* / Q000633:toxicity*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000627:therapeutic use / Q000633:toxicity; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007773:Lactates / Q000097:blood; D016031:Liver Transplantation; D016032:Randomized Controlled Trials as Topic
chemical_list: D000998:Antiviral Agents; D007773:Lactates; D001086:Arabinofuranosyluracil; C043457:fialuridine